Trial reportAnnals of oncology : official journal of the European Society for Medical Oncology2010
A phase II study of bevacizumab, oxaliplatin, and docetaxel in locally advanced and metastatic gastric and gastroesophageal junction cancers.
Trial report in Annals of oncology : official journal of the European Society for Medical Oncology, 2010. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 45 papers, 3 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
45 citing papers in PubMed, 3 syntheses or guidelines pooled it, 97 citations in OpenAlex.
- Treatment outcome of anti-angiogenesis through VEGF-pathway in the management of gastric cancer: a systematic review of phase II and III clinical trials.BMC research notes · 2018Pooled it
- Anti-angiogenic Therapy in Patients with Advanced Gastric and Gastroesophageal Junction Cancer: A Systematic Review.Cancer research and treatment · 2017Pooled it
- Prognostic significance of vascular endothelial growth factor immunohistochemical expression in gastric cancer: a meta-analysis.Molecular biology reports · 2012Pooled it
- Trial
- Phase II study of modified docetaxel, cisplatin, and fluorouracil with bevacizumab in patients with metastatic gastroesophageal adenocarcinoma.Journal of clinical oncology : official journal of the American Society of Clinical Oncology · 2011Trial
- Review
- The Role of Angiogenesis Targeted Therapies in Metastatic Advanced Gastric Cancer: A Narrative Review.Journal of clinical medicine · 2023Review
- Photothermally responsive theranostic nanocomposites for near-infrared light triggered drug release and enhanced synergism of photothermo-chemotherapy for gastric cancer.Bioengineering & translational medicine · 2023Article
- Review
- Current treatments and outlook in adenocarcinoma of the esophagogastric junction: a narrative review.Annals of translational medicine · 2022Review
- Successes and failures of angiogenesis blockade in gastric and gastro-esophageal junction adenocarcinoma.Frontiers in oncology · 2022Review
- Current Molecular Targeted Agents for Advanced Gastric Cancer.OncoTargets and therapy · 2020Review
- A systematic review and meta-analysis on the effect of angiogenesis blockade for the treatment of gastric cancer.OncoTargets and therapy · 2018Article
- Correlations between VEGF-A expression and prognosis in patients with gastric adenocarcinoma.International journal of clinical and experimental pathology · 2017Article
- Exploring the role of molecular biomarkers as a potential weapon against gastric cancer: A review of the literature.World journal of gastroenterology · 2016Review
- Targeted therapies in gastric cancer treatment: where we are and where we are going.Investigational new drugs · 2016Review
- Targeted therapies in gastric cancer and future perspectives.World journal of gastroenterology · 2016Review
- Angiogenesis inhibitors in gastric and gastroesophageal junction cancer.Gastric cancer : official journal of the International Gastric Cancer Association and the Japanese Gastric Cancer Association · 2016Review
- Monoclonal antibodies-based treatment in gastric cancer: current status and future perspectives.Tumour biology : the journal of the International Society for Oncodevelopmental Biology and Medicine · 2016Review
- Vascular endothelial growth factor a inhibition in gastric cancer.Gastric cancer : official journal of the International Gastric Cancer Association and the Japanese Gastric Cancer Association · 2015Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
13 authors at 3 institutions in 1 country.
Funding
Abstract
backgroundBevacizumab has demonstrated antitumor activity in multiple diseases. This phase II study was undertaken to determine the effects of adding bevacizumab to a regimen of docetaxel and oxaliplatin in patients with advanced adenocarcinoma of the stomach or gastroesophageal junction. PATIENTS AND
methodsPreviously untreated patients with locally advanced or metastatic disease and a performance status (PS) of 0-1 were eligible for this study. Patients received bevacizumab at 7.5 mg/kg, docetaxel at 70 mg/m(2), and oxaliplatin at 75 mg/m(2) administered on day 1 of a 21-day cycle. The primary end point of the study was progression-free survival (PFS).
resultsA total of 38 eligible patients (median age 57 years, 45% gastric, 55% PS 0) were enrolled on to the study. Median PFS was 6.6 months [95% confidence interval (CI) 4.4-10.5] and median survival 11.1 months (95% CI 8.2-15.3). Complete responses were documented in 2 (5%) patients, partial responses in 14 (37%), and stable disease in 14 (37%). No treatment-related deaths were observed. The most commonly reported grade 3-4 toxicity was neutropenia (34%), and gastrointestinal perforation occurred in three patients (8%).
conclusionThe combination of bevacizumab, docetaxel, and oxaliplatin has promising activity for further evaluation in randomized trials.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.